Research questions
To what extent can integrated genomic and proteomic profiles reveal unique COPD molecular subtypes, and what novel genetic variants and proteins define these subtypes and their underlying molecular pathways, ultimately informing precision medicine and drug target identification?
Objectives
To identify and characterize unique COPD molecular subtypes, discover their defining genomic and proteomic features, validate their clinical relevance with patient outcomes, and predict potential drug targets and repurposing strategies.
Scientific rationale
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally, affecting over 200 million people and imposing a heavy burden on healthcare systems and economies [1]. The significant heterogeneity of COPD means that a ‘one-size-fits-all’ therapeutic approach is largely ineffective [2]. This heterogeneity is a primary reason why existing therapies have had limited success in altering the disease course.
This study aims to address this challenge by integrating genomic and proteomic data from the UK Biobank cohort to explore COPD’s molecular heterogeneity. Genomics provides insights into genetic susceptibility, while proteomics reveals functional changes that are the direct drivers of disease [3]. Multi-omics integration is a cornerstone of precision medicine, enabling the systematic identification of novel COPD subtypes (endotypes) and potential therapeutic targets [4].
The expected findings include the identification of novel COPD molecular subtypes, the discovery of biomarkers for early diagnosis and prognosis, the elucidation of molecular mechanisms, and the identification of actionable therapeutic targets for personalized medicine. This research aims to provide a robust framework for precise diagnosis, prognosis, and treatment of COPD, ultimately improving patient quality of life.
